

FIG. 1




FIG. 2




FIG 3




FIG. 4

Fusion 1 and 2
1) Immunogen 12 ($T = K LH$, 12a), classical regimen

- 2) 3.7×10^8 lymphocytes total
 3) Fusion 1 = R0 myeloma, Fusion 2 = P3 myeloma, 47 plates each
 4) Screened on MDMA-BSA 12 (T = BSA, 12b) (in the presence and absence of 10% FBS)

Fusion 3 (11 weeks later)

- 1) Immunogen 12 ($T = KLH$), deprotected, classical regimen
- 2) 1.45×10^8 lymphocytes, 36 plates
- 3) 12 selected from 1,979 wells tested, same testing protocol as in Fusions 1 and 2.

Table 1

FIG. 5




FIG. 6




FIG. 7




FIG. 8

MDMA 2.1.1 Cross-Reactivity in Modified Roche OnLine Format

MDMA calibrators

	[MDMA] ng/ml	Rate	
S1	0	15842	
S2	250	12977	
S3	500	10996	
S4	1000	9434	
S5	3000	8043	
Total		7799	

Span Data

	Drug	Amount spiked ng/ml	Instrument reading	% CR
	d-MAMP	625	0	0
	d-AMP	625	0	0
	MDMA	625	714	114.2
	MDEA	625	1864	298.2
	BDB	5000	195	3.9
	MBDB	5000	625	12.5
	PPA	200000	0	0
	Phent	200000	0	0
	Phendim	200000	0	0
	Tyramine	200000	0	0
	l-eph	200000	0	0
	d-pseudoeoph	200000	0	0
	l-AMF	200000	0	0
	l-MAMP	200000	170	0.09

